Stayble Therapeutics AB (publ) (STABL.ST)

SEK 0.39

(1.56%)

Market Cap (In SEK)

17.05 Million

Revenue (In SEK)

-

Net Income (In SEK)

-23.73 Million

Avg. Volume

1.23 Million

Currency
SEK
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
0.19-1.05
PE
-
EPS
-
Beta Value
0.23
ISIN
SE0013513652
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Andreas Gerward M.Sc.
Employee Count
-
Website
https://www.staybletherapeutics.se
Ipo Date
2020-03-09
Details
Stayble Therapeutics AB (publ) develops injectable treatment for chronic low back pain triggered by disc degeneration. The company develops STA363, a minimally invasive single injection of the drug into the disc that targets chronic low back pain. Stayble Therapeutics AB (publ) was incorporated in 2015 and is based in Gothenburg, Sweden.